🔴 Neuronetics is trading 5.8% down without a fresh company catalyst

Neuronetics is trading at $2.21, down -5.77%, with no fresh company-specific announcement identified to explain the October 1 decline.

• Neuronetics’ investor-relations release page lists earlier announcements, but no new October 1 catalyst.
• The decline coincided with healthcare-sector weakness and a rise in Treasury yields. The 10-year yield reached 5.33%, its highest level since early 2002, amid inflation and fiscal concerns; available evidence does not establish these factors as the direct cause.